



How to cite this paper: Papoyan, T., (2023). The Importance of Drug Safety and the Strategies for Promoting it. *Messenger of ASUE*, 3(75), 61-68. DOI: 10.52174/1829-0280_2023.3-61

Received: 19.10.2023. **Revision:** 27.10.2023. **Accepted:** 28.12.2023.

TATSHAT PAPOYAN

*PhD student of the Chair of Statistics
at Armenian State University of Economics*

 <https://orcid.org/0009-0002-8525-110X>

THE IMPORTANCE OF DRUG SAFETY AND THE STRATEGIES FOR PROMOTING IT

With medications becoming the standard of treatment for many illnesses these days, drug safety has turned into a high priority in contemporary healthcare. Medicines might offer therapeutic benefits but carry side effects and risks. Drug safety is crucial for positive patient outcome, injury prevention, and lower healthcare expenditures. This particular paper offers a sweeping review of the significance of drug safety and also covers drug development, regulation, surveillance and control of unwanted side effects.

The literature review points to the difficulty of drug safety because of patient variables including age, health condition and concurrent medicine. Specific care is required for vulnerable groups - people that are older, kids or even pregnant - who present considerable safety risks. Preclinical testing is informative but clinical trials with human subjects are still crucial for evaluating efficacy and drug safety before marketing.

The paper discusses the crucial role of drug safety in public health and also offers views on its intricacy and advancement methods.

Keywords: *drug safety, adverse effects, drug development, drug regulation, adverse event reporting*

JEL: I12, L65

DOI: 10.52174/1829-0280_2023.3-61

INTRODUCTION. Contemporary medicine is extremely concerned with drug safety. Millions of people take medicines to deal with their illnesses, but these same medicines can have unwanted side effects - some deadly. Drug safety is

vital for patient satisfaction, harm prevention and healthcare costs. Hence, effective and safe drugs are a public health need. The given article reviews the significance of drug safety and the associated areas of drug safety - drug development, regulation, monitoring and control of negative effects, and considers the methods to promote this particular subject in the healthcare system.

The scientific novelty of the current study is its multidimensional examination of drug safety. It offers a current look at the significance of drug safety and outlines the need for highly effective promotion. While a lot is known regarding drug safety, this research combines information from several angles, for instance, regulatory guidelines, empirical investigation, along with statistics, to provide people with the present and the majority of correct picture of drug safety and the public health effect.

Besides a generic discussion of drug safety, subjects discussed include drug development, monitoring, regulation, side effects management and drug safety promotion methods. It stresses the need for integrating patient age, health status, along with concurrent medication usage into drug safety assessments. It also points out the importance of post-marketing monitoring, adverse event reporting and patient engagement for drug safety.

Additionally, the article recognizes the necessity for joint efforts between doctors and pharmaceutical companies in carrying out drug safety improvement methods. Insisting on effective action all through the drug development process and healthcare system, current practice and future perspectives on drug safety are pointed out.

Generally, the scientific novelty of the present study is its current and comprehensive debate on the subject of drug safety, its complicated character and its promotion. Consolidating evidence from various angles and also addressing essential issues regarding drug safety, the article enhances the body of understanding and knowledge on this crucial subject in modern medicine.

LITERATURE REVIEW. The literature review highlights the essential value of drug safety in healthcare and its influence on patient outcomes and healthcare expenses. For Prajapati and others drug safety is determined by objective criteria involving medication pharmacokinetics and metabolism which might have negative effects in low-risk patient populations and in interaction with some other medications. Drug safety is a multifaceted idea influenced by patient age, lifestyle along with other medicines. The elderly, pregnant women, children make up a vulnerable group which presents a greater safety threat to the overall population. The presence of several chronic conditions with several medications in older people raises the likelihood of toxic drug interactions. But depending on the age of the pediatric patients many of their organs are still at a developmental phase and consequently their metabolisms might vary therefore

boosting toxic levels of a drug. In the female pregnant state, medication can ruin the developing fetus of the uterus (Parajapati et al., 2023).

Information regarding drug safety at the drug development phase is frequently incomplete due to preclinical testing - the animal tests of medications for efficacy and safety. Though the findings from animal experiments are not always directly relevant to people. There are biological differences between animal types and humans which could influence drug metabolism and side effects. Hence, preclinical testing is instructive about drug effectiveness but does not ensure the drug's behavior in humans. Hence, additional clinical trials utilizing human subjects are required to verify the safety and usefulness of the medication before it is placed on mass production. Clinical trials offer crucial information regarding human drug safety and help in determining unwanted side effects not previously observed in animal studies (Maqbool et al., 2019, p. 544).

RESEARCH METHODOLOGY. Literature Review: This article has utilized a systematic literature review to find literature related to drug safety and drug promotion methods. Related articles, research papers and reports have been investigated utilizing academic databases including PubMed, Scopus and Google Scholar. Keywords and search terms include "drug safety," "medication safety," "adverse effects," "drug development," "regulation," "clinical trials," "post-marketing surveillance," and "patient education".

Data Collection: The literature review incorporates data from academic journals, regulatory guidance documents, reports coming from international organizations (including the World Health Organization and also the Food and Drug Administration) and statistics on drug related adverse events, mortality and hospitalizations. These sources have supplied information on drug safety concerns and public health effects.

Data Analysis: Data collected have been analyzed to identify themes, trends and findings regarding drug safety and drug promotion. The analysis synthesizes information from different sources. The results support the arguments and assertions made in the article.

Integration of Findings: Literature review and data analysis conclusions are synthesized to explain the significance of drug safety and the promotion of drug safety. The article attempts to balance the evidence by highlighting various viewpoints.

Writing and Reviewing: The article is written from synthesized data and formatted in the conventional academic article format. Clarity, coherence, and logical progression of ideas have been very carefully considered. Then the article has been critically analyzed and revised many times for content and quality control.

Citations and Referencing: Proper citations and referencing are given throughout the article to acknowledge the sources and to offer readers links to the initial research papers and reports.

Peer Review: The content has been peer reviewed to validate its rigor and credibility. Feedback and suggestions coming from drug safety subject-matter specialists are in the article.

Following these methodologic methods, this study attempts to give an evidence-based and systematic assessment of the role of drug safety and the approaches to drug safety promotion in the healthcare system.

ANALYSIS. *The Importance of Drug Safety.* Drug safety is crucial to ensure that individuals receive the therapeutic benefit from medicine without side effects or harm. Poor drug safety control might lead to serious health results including hospitalization, death and disability (Thomas et al., 2022). In 2022, the World Health Organization (WHO) estimated that 270 million individuals (or around 5.5% of the worldwide population aged 15-64) used psychoactive drugs and around thirty five million are suffering from among the drugs problems (harmful pattern of drug use or drug dependency). Drug use kills an estimated 0.5 million people each year including 350 000 men along with 150 000 women. The latest mortality patterns in certain high-income nations mirror opioid-related deaths mostly driven by synthetic opioids. Additionally to this, drug use contributed over forty two million years of healthy living loss (DALY) in 2017 corresponding to more or less 1.3% of the worldwide disease burden. In the world there are believed to be more or less eleven million users of injecting Drugs; 1.4 million are HIV positive and 5.6 million are hepatitis C (WHO, Drugs, 2022). Consequently, safe drug safety strategies are crucial for minimizing damage and enhancing patient outcomes.

The pharmaceutical industry is among the key drug safety stakeholders. The industry must perform clinical trials and extensive testing prior to approving new medicines for the use in patients. When a medication is approved, providers have to monitor its usage and report side effects. The Food and drug Administration (FDA) may be the federal body which controls Drug safety in the United States and can recall harmful medicines off the marketplace (FDA).

The drug development system is an expensive and lengthy process which could take years to finish. The process encompasses several steps from preclinical research, clinical studies in addition to regulatory approval. The effectiveness and safety of a novel drug are tested in preclinical research before it is placed into humans. The safety and efficacy of the drug in human beings are subsequently tested in clinical trials through many phases. Before a Drug can be marketed it first of all has to be given regulatory approval from government agencies like the US Food and drug Administration (FDA, 2022, URL portal, 9).

In their current state, these measures make cancer the most common therapeutic target for new drugs, possibly a third of these are claimed items in this field. At present here are the rankings for such cases as heart disease, NSC disease, nervous system and immune system diseases. CDER reports that there were 15633 different NMDs and non-biosimilar IND undergoing different phases of development cycle in 2022. Specifically, 9126 of which were commercial INDs and 6507 of which were research INDs.

At the same time, the U.S. regulatory applications for the development of new drugs (with the best available data) continue to increase, as shown by the number of new INDs (or original INDs) filed, while the proportion of commercial INDs (or traditional INDs) continues to increase (see Table 1).

Table 1

Potential new drugs in clinical trials in the United States by primary disease/medicine use by June 2022¹

<i>Disease/Medical Use</i>	<i>Number of potential new drugs in US Clinical Trials</i>
Total number of new drugs currently in clinical trials in the USA	454 305
Symptoms and General Pathology	577683
Neoplasms	499392
Urinary Tract, Sexual Organs and Pregnancy Conditions	379786
Infections	369835
Nervous System Diseases	340968
Digestive System Diseases	261402
Behaviors and Mental Disorders	247014
Respiratory Tract (Lung and Bronchial) Diseases	236402
Heart and Blood Diseases	232735
Immune System Diseases	201986
Nutritional and Metabolic Disease	182440
Blood and Lymph Conditions	149584
Skin and Connective Tissue Diseases	129014
Musculoskeletal Diseases	122673
Gland and Hormone Related Diseases	103739
Diseases and Abnormalities at or Before Birth	88996
Wounds and Injuries	69817
Eye Diseases	58150
Mouth and Tooth Diseases	44109
Ear, Nose and Throat Diseases	32475
Occupational Diseases	1213
Disorders of Environmental Origin	38

Drug Regulation: The effectiveness and safety of drugs can only be verified under strict regulation by regulators such as FDA. They assess whether a drug is safe and works as it should for its designated purpose using data from preclinical and clinical tests. All medicines to be released into the USA market should pass the FDA test. The agency also makes the drug manufacturers report on any of the untoward effects that may be connected to the products.

¹ Created by the author using the data from <https://clinicaltrials.gov/>

Drug Monitoring: After a drug receives marketing authorization, its effectiveness and safety must be maintained. Post-marketing surveillance is crucial for detecting and managing side effects which arise once a drug qualifies for commercialization. Drug manufacturers have to report adverse effects of the products in order to the FDA along with other regulatory bodies; the data are utilized to rectify the product labeling and also to alert doctors and patients of the medication (WHO, 2022).

Management of Adverse Effects: Even strict monitoring and tests of drugs may have side effects. Healthcare providers are essential in addressing these negative effects. They must know the dangers of the medications they prescribe and monitor their patients for negative effects. Pirmohamed and Breckenridge (2014) determined that medication related adverse events represent 5-6% of all hospitalizations and as much as 5% of clinic expenditure. Negligent drug functions by themselves kill around 7,000 individuals each year in the United States.

Patients also manage the dangers of their medicines. They should be advised of potential unwanted side effects of the medicines and quickly inform their physicians in case they encounter new symptoms (CDC, 2022). In result patients' engagement and active involvement in their own individual healthcare enhance medication safety and reduce side effects.

Development costs increase quickly in time and in progress - once the first vanilla in human trials (FIMs), costs are talked about first in the tens of millions and (generally) before marketing approval applications in the hundreds of millions. It takes years after the molecules are chosen to be transformed into medications. Again, it may be disputed how many (five to 16 years typically cover the extreme range) and at no stage is the success (commercialization approval and economic therapeutic use) guaranteed.

These truths collectively accomplish the core fundamental broad-based objectives of drug development strategy:

1. Kill the losers first so no money goes to waste on them.
2. Do everything to shorten drug development time.

These ideas result in various methods in nonclinical safety evaluation of drugs that may be illustrated by two extreme cases.

Due to financial restrictions and also the expectation that the candidate therapeutic is licensed to or partnered with a big company at an optimal point in development (usually after FIM/Phase I trials or a "proof of concept" Phase II trial), only the technical and regulatory steps required to get a molecule to this point will be performed (Dexter and Shayne, 2023, p. 13).

This counsel is absolutely necessary (though not always entirely sufficient) for anybody taking this case.

The traditional big firm model focuses on minimizing the risk of eventual failure. Studies and technical activities are not reduced to a minimum but are augmented by extra elements. Development is governed by a group of clearly

outlined and consistently analyzed "go-no-go" decision points. Many of the additional components are either limited, non-GLP studies that will be required later (such as Ames, acute toxicity, hERGs at just one concentration, and 7 days to 4 days repeat dose studies) or studies that are affordable and might be accomplished later (CYP inhibitors, metabolic stability, induction, and longer than necessary repeat dose toxicity studies before proceeding into Phase II). What "extra" elements are added vary by the firm and generally reflect exactly what the organization or employees have previously experienced.

Investigations needed to meet regulatory nonclinical safety assessment criteria (i.e., all supported metabolic and toxicokinetic research and activities) might be classified into three broad categories:

- a. Those that requisite for the filing of an IND, CTA or other equivalent application and consequent FIM clinical investigations.
- b. Those required for continuation of clinical evaluation and drug development through to and including successful Phase III studies.
- c. Those studies which are necessary only to verify a marketing approval application (NDA, similar) or BLA. Examples of this group consist of cancer toxicity research and formal reproductive (versus prenatal) toxicity investigations.

The question which studies belong to which group is rather variable depending on the patient population being served (therapeutic claim) and the drug action.

CONCLUSIONS. Today's medicine requires drug safety, which is crucial for achieving good patient outcome, minimizing damage, and lowering healthcare expenditures. The figures demonstrate the magnitude of drug use and unwanted side effects on worldwide health. Drug safety - medication development and regulation, monitoring and control of negative effects are vital to keep effective and safe drugs. The drug development process entails several stages from preclinical research, clinical trials in addition to regulatory approval. Regulators like the FDA are vital in keeping drugs effective and safe. When a drug is marketed, its effectiveness and safety must be monitored. Patients and physicians need to be aware of the medication - associated risks and actively engage in reversing adverse effects. Crucial to drug safety tends to be adverse event reporting, post marketing monitoring, risk management plans, patient knowledge, and pharmacovigilance. These tactics should be implemented together by pharmaceutical companies and healthcare providers to supply patients with effective and safe medications. Drug safety programs must minimize harm and enhance patient outcomes. They ought to include thorough testing, monitoring of adverse effects, active training and engagement of patients and doctors.

In conclusion, drug safety is extremely important for public health and excellent health outcomes for the patient. Strong strategies depending on the

way of drug development, regulatory approval and medical approaches could make medications a lot less risky and stable in the long run. Continued research, collaboration and education are decisive to enhance drug safety and healthcare results.

References

1. Centers for Disease Control and Prevention. (2022). *Medication Safety Program*. <https://www.cdc.gov/medicationsafety/index.html>
2. Institute for Safe Medication Practices. <https://www.ismp.org/resources/education-predictably-disappointing-and-should-never-be-relied-upon-alone-improve-safety>
3. Maqbool M, Dar MA, Rasool S, Bhat AU, Geer MI, *Drug safety and Pharmacovigilance: An overview*, Journal of Drug Delivery and Therapeutics. 2019; 9(2-s):543-548. <http://dx.doi.org/10.22270/jddt.v9i2-s.2469>
4. Prajapati, S., Tao, R., & Feldman, S. R. (2023). *Drug tolerability versus drug safety. The Journal of dermatological treatment*, 34(1), 2202786. <https://doi.org/10.1080/09546634.2023.2202786>
5. Pirmohamed, M., & Breckenridge, A. (2014). *Patient safety of medicines: a new approach. Clinical pharmacology and therapeutics*, 95(5), 453-564.
6. Gad, S. C., & Sullivan, D. W., Jr. (2023). *Drug safety evaluation*. John Wiley & Sons.
7. Rodziewicz, T. L., Houseman, B., & Hipskind, J. E. (2023). *Medical Error Reduction and Prevention*. In StatPearls. StatPearls Publishing.
8. U.S. Food and Drug Administration. *Advances in FDA's Safety Program for Marketed Drugs*. <https://www.fda.gov/files/drugs/published/Advances-in-FDA%27s-Safety-Program-for-Marketed-Drugs-%28PDF---188KB%29.pdf>
9. U.S. Food and Drug Administration. (2022). *The Drug Development Process*. <https://www.fda.gov/patients/learn-about-drug-and-device-approvals/drug-development-process>
10. U.S. Food and Drug Administration. (2022). *Postmarket Drug Safety Information for Patients and Providers*. <https://www.fda.gov/drugs/drug-safety-and-availability/postmarket-drug-safety-information-patients-and-providers>
11. World Health Organization. *Drugs (psychoactive)*. https://www.who.int/health-topics/drugs-psychoactive#tab=tab_2
12. World Health Organization. (2022). *Pharmacovigilance*. https://www.who.int/medicines/areas/quality_safety/safety_efficiency/pharmacovigilance/en/
13. <https://clinicaltrials.gov/>